Day One Biopharmaceuticals Deregisters Unsold Securities Following Servier Acquisition

summarizeSummary

Day One Biopharmaceuticals has filed to deregister all unsold securities from its prior S-3 registration statements, a procedural step following its acquisition by Servier.

check_boxKey Events

• Deregistration of Securities

  Day One Biopharmaceuticals has filed Post-Effective Amendments to its S-3 registration statements (No. 333-274521 and No. 333-281822) to deregister all unsold securities.

• Consequence of Merger Completion

  This deregistration follows the successful completion of the merger with Servier Detroit Inc., a direct wholly-owned subsidiary of Servier Pharmaceuticals LLC, on April 23, 2026.

• Transition to Private Entity

  As a result of the merger, Day One Biopharmaceuticals is now a wholly-owned subsidiary of Servier, terminating any need for public offerings and sales of its securities.

auto_awesomeAnalysis

This POSASR filing formally deregisters all unsold securities from Day One Biopharmaceuticals' previous S-3 registration statements. This action is a direct and expected consequence of Servier's successful tender offer and subsequent merger, which was completed on the same day. With Day One Biopharmaceuticals now operating as a wholly-owned subsidiary of Servier, it no longer requires public registration for its securities, marking its transition from a publicly traded entity.